A prospective, randomised trial has shown that standard adjuvant chemotherapy is superior to capecitabine in the treatment of women with breast cancer aged 65 years or older; on the basis of the results of this study, capecitabine cannot be recommended in this setting.
Related Articles
Drug Watch
PHARE: shining a light for academic research in Europe
Focus
What’s brave about having cancer?
Senza categoria
Leave a Reply